IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applica	ant(s):	Jacob Waugh et al.	Confirmation No:	1919		
Serial No.:		10/591,485	Group Art Unit:	1656		
Filed:		November 7, 2007	Examiner:	Samuel W. Liu		
For:		Multi-Component Biological Transport Systems				
P.O. Bo	ox 1450	for Patents A 22313-1450				
	<u>st</u>	PPLEMENTAL INFORMAT	ION DISCLOSURE S	TATEMENT		
Sir:						
		This Information Disclosure Stat	ement is filed in accord	lance with 37 C.F.R.		
§§1.56	, 1.97 ar	nd 1.98. The items listed on Form	n PTO-SB08, a copy of	which is enclosed, are		
made o	f record	to assist the Patent and Tradema	ark Office in its examin	ation of this application.		
The Ex	aminer	is respectfully requested to fully	consider the items and	to independently ascertain		
their te	aching.					
1.	not i	For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:				
2.	not i	For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.	encle	Any copy of the items listed on the enclosed copy of Form PTO-SB08 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed				
		·				
4. 🛛		ee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement it is being filed in compliance with:				
		37 C.F.R. §1.97(b)(1), within application other than a CPA;		ng date of a national		
		37 C.F.R. §1.97(b)(2), within national stage as set forth in §		_		

			merits; or	
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.	
5.		since in par Allow	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one o the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
6.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statemen it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):		
			A check in the amount of \$180.00 is enclosed in payment of the fee.	
			Charge the fee to Deposit Account No. <u>50-3732</u> , Order No	
7.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Stater it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing dat action or a notice of allowance, whichever comes first, but before payment of fee, and is accompanied by:		
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and	
			ne fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.	
8.	This Information Disclosure Statement is being filed in o		nformation Disclosure Statement is being filed in compliance with:	
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
		b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
		c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.	
9.			by certify that each item of information contained in this Information Disclosure nent was first cited in a communication from a foreign patent office in a	

	counterpart foreign application not mo Information Disclosure Statement.	ore than three months prior to the filing of this				
	filed herewith was cited in a communicounterpart foreign application or, to r	ation in the Information Disclosure Statement cation from a foreign patent office in a my knowledge after making reasonable inquiry, ed in §1.56(c) more than three months prior to re Statement.				
10.	This document is accompanied by \square a Search Report \square Communication which was cited in a corresponding \square PCT or \square Foreign counterpart application.					
11.	A check in the amount of \$ is enclosed in payment of the fees due under 3 C.F.R. §§1.17(h) and 1.17(p).					
	Charge any fees due under 37 C.F.R. § 50-3732, Order No	§§1.17(h) and 1.17(p) to Deposit Account No.				
\boxtimes	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105074.					
Dated: October 5, 2010 By:		Respectfully submitted, KING & SPALDING LLP				
		Joseph D. Eng, Jr. Reg. No. 54,084				
Correspo:	ndence Address:					
King & Spalding LLP						
1185 Avenue of the Americas						
New York NY 10036						

New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile